
Datroway First TROP2 ADC Approved for First-line mTNBC (PD-1/PD-L1 Ineligible)
Datroway® Receives U.S. FDA Approval as First TROP2-Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple-Negative Breast Cancer in Patients Not Eligible for PD-1/PD-L1 Inhibitor Therapy Daiichi Sankyo and…












